EyeWorld Asia-Pacific September 2021 Issue

REFRACTIVE EWAP SEPTEMBER 2021 35 acceptance than PRK.” Dr. Reinstein said that any myopic eye, without the usual contraindications for refractive surgery, is a candidate for SMILE. The procedure is especially desirable for eyes that might be slightly dry, for those with large pupils, and/ or for patients who play contact sports, he said. From a surgeon standpoint, Dr. Hamilton said the initial slower recovery of SMILE compared to LASIK might have kept refractive surgeons from adopting the technology and technique when it was first approÛed. ewer energy settings make this a non-issue now, Dr. Hamilton said. He recently published an article comparing visual acuities and higher order aberrations of his LASIK and SMILE patients on postop day 1 and month 1. 1 The study found visual acuities were equivalent on postop day 1 and month 1 between the procedures. It also showed less spherical aberration induction at month 1 with SMILE vs. LASIK. “That was a big hurdle for SMILE to get over,” Dr. Hamilton said, noting how it used to take a week or longer for SMILE patients to reach 20/20 vision. “Now with the newer energy settings, we have less issues with inyammation postoperatively. Opaque bubble layer (the whitening of the cornea) is much less with the newer energy settings, and that translates to faster vision recovery.” Dr. Hamilton called this the most important new development for SMILE. Another attractive feature, he continued, is its accuracy and predictability. “If you talk to refractive surgeons around the world who do SMILE and LASIK, they will tell you that the enhancement rate with SMILE is one-third that of LASIK,” the latter of which already has a low enhancement rate. Dr. Doane also mentioned the lower enhancement rate experienced with SMILE. The reason for this, Dr. Hamilton explained, could be that the tissue is not being exposed to the environment for a variable length of time as it is when the yap is lifted in Ƃ- and the treatment proceeds. A –9 D LASIK correction, for example, would result in the tissue being exposed for longer than a –1 D correction. In SMILE, however, the time the laser is firing to create the lenticule is the same regardless of the correction amount. “The variability in terms of the depth of a femto laser cut primarily comes from the variability in the disposable interface with the eye. … With SMILE, because you’re doing two cuts with the same interface, any kind of variability subtracts outÆ that½s something that hasn½t been talked about much that is also contributing to the higher predictability of the procedure. I’m at a point now where if I have a patient with SMILE who is off and needs an enhancement, which is less than 1% of the time, it’s probably a function of the preoperative refraction,” Dr. Hamilton said. One barrier to SMILE adoption from a surgeon standpoint is the need to purchase additional technology. The procedure currently approved in the U.S. uses the VisuMax laser platform (ReLEx SMILE, Carl Zeiss Meditec). Other companies are working on laser platforms that could perform SMILE procedures, though they’re not yet approved in the U.S. Once more devices to perform SMILE or lenticule extraction reach the U.S. market, Dr. Doane said the technique will achieve further validation in the refractiÛe surgery field and even wider acceptance as a whole. Dr. Reinstein noted that one should expect a settling period with new devices. “It took the VisuMax close to 5 years to reach clinical equivalency to LASIK from building and releasing the device itself,” Dr. Reinstein said. “Our textbook contains a road map for new companies to work from, which will shorten this time, but femto cutting is a delicate balance of parameters, and each laser is different.” There are several parameter adjustments with the current SMILE procedure that are likely to come to the U.S. with FDA approval as well, Dr. Doane said. These include the ability to treat lower and higher amounts of astigmatismÆ the ability to treat lower myopic sphere (currently to treat astigmatism, at least –1 D of sphere needs to be corrected)Æ and the ability to treat up to 2 D more sphere than the current 10 D. Dr. Reinstein said SMILE approval for hyperopia is in the near future, with the 12-month outcomes from his investigator- initiated trial conducted with Kishore Pradhan, MD, in Nepal published in 2019. 2 EWAP Reference 1. Hamilton D, et al. Comparison of early visual outcomes after low-energy SMILE, high-energy SMILE, and LASIK for myopia and myopic astigmatism in the United States. J Cataract Refract Surg . 2ä2£Æ{Ç\£8q2È. 2. Pradhan KR, et al. Small incision lenticule extraction (SMILE) for hyperopia: 12-month refractive and visual outcomes. J Refract Surg . 2䣙ÆÎx\{{2 –450. Editors’ note: Dr. Doane practices at Discover Vision Center, Kansas City, Missouri, and has interests with Carl Zeiss Meditec. Dr. Hamilton is Medical Director, Hamilton Eye Institute, Los Angeles, California, and has interests with Carl Zeiss Meditec and Johnson & Johnson Vision. Dr. Reinstein practices at London Vision Clinic, London, UK, and has interests with Carl Zeiss Meditec.